Favipiravir
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319889

CAS#: 259793-96-9

Description: Favipiravir, also known as Favilavir, T705, or Avigan, is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.

Chemical Structure

img
Favipiravir
CAS# 259793-96-9
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 319889
Name: Favipiravir
CAS#: 259793-96-9
Chemical Formula: C5H4FN3O2
Exact Mass: 157.03
Molecular Weight: 157.104
Elemental Analysis: C, 38.23; H, 2.57; F, 12.09; N, 26.75; O, 20.37

Price and Availability

Size Price Availability Quantity
200mg USD 150 Ready to ship
500mg USD 250 Ready to ship
1g USD 450 Ready to ship
2g USD 750 Ready to ship
Bulk inquiry

Synonym: T705; T-705; T 705; Avigan; Favipiravir; Favilavir;

IUPAC/Chemical Name: 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide

InChi Key: ZCGNOVWYSGBHAU-UHFFFAOYSA-N

InChi Code: InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

SMILES Code: O=C(C1=NC(F)=CN=C1O)N

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Our product Favipiravir is a raw chemical in Powder form for laboratory research use only. It is NOT a FDA approved medicine, and can NOT be used for any treatment or clinical trials on humans! Your order will NOT be fulfilled unless academic or government institutes!

Biological target: Favipiravir (T-705) is a viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5’-triphosphate (RTP).
In vitro activity: This study has extended the spectrum of T-705, demonstrating robust antiviral activity against CDV (canine distemper virus) in vitro. Results in this work indicated that T-705 effectively suppressed CDV-3 and CDV-11 in Vero and DH82 cells. In Vero cells, the IC50 of T-705 against CDV was 25.2 μg/ml for CDV-3 and 7.05 μg/ml for CDV-11. In DH82 cells, the IC50 of T-705 against CDV was 33.54 μg/ml for CDV-3 and 16.97 μg/ml for CDV-11. These findings were comparable to those reported for other RNA viruses, including West Nile virus (IC50: 53 μg/ml), foot-and-mouth disease virus (IC50: 14 μg/ml), Ebolavirus (IC50: 10.5 μg/ml), murine norovirus (IC50: 39 μg/ml) and Zika virus (IC50:17.4 μg/ml). Reference: BMC Vet Res. 2019; 15: 316. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720089/
In vivo activity: However, when tested in IFNAR−/− mice, ribavirin did not protect mice from lethal ZIKV challenge, as shown before with male STAT1−/− mice. In contrast, daily administration of 300 mg/kg favipiravir protected the IFNAR−/− mice from lethal ZIKV challenge (Figure 2). This is consistent with results from another flavivirus, yellow fever virus, where favipiravir improved disease outcome in the hamster model. Additionally, favipiravir, but not ribavirin, is an effective treatment against other RNA virus infections, such as CCHFV, for which it has been shown to protect mice and macaques from lethal disease. Reference: Microorganisms. 2021 May 29;9(6):1178. https://pubmed.ncbi.nlm.nih.gov/34072604/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 44.2 281.21
Ethanol 1.8 11.33
Water 4.1 26.29

Preparing Stock Solutions

The following data is based on the product molecular weight 157.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Xue X, Zhu Y, Yan L, Wong G, Sun P, Zheng X, Xia X. Antiviral efficacy of favipiravir against canine distemper virus infection in vitro. BMC Vet Res. 2019 Sep 2;15(1):316. doi: 10.1186/s12917-019-2057-8. PMID: 31477101; PMCID: PMC6720089. 2. Jochmans D, van Nieuwkoop S, Smits SL, Neyts J, Fouchier RA, van den Hoogen BG. Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4620-9. doi: 10.1128/AAC.00709-16. PMID: 27185803; PMCID: PMC4958190. 3. Matz K, Emanuel J, Callison J, Gardner D, Rosenke R, Mercado-Hernandez R, Williamson BN, Feldmann H, Marzi A. Favipiravir (T-705) Protects IFNAR-/- Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner. Microorganisms. 2021 May 29;9(6):1178. doi: 10.3390/microorganisms9061178. PMID: 34072604. 4. Jacobs S, Wang L, Rosales Rosas AL, Van Berwaer R, Vanderlinden E, Failloux AB, Naesens L, Delang L. Favipiravir Does Not Inhibit Chikungunya Virus Replication in Mosquito Cells and Aedes aegypti Mosquitoes. Microorganisms. 2021 Apr 27;9(5):944. doi: 10.3390/microorganisms9050944. PMID: 33925738; PMCID: PMC8145424.
In vitro protocol: 1. Xue X, Zhu Y, Yan L, Wong G, Sun P, Zheng X, Xia X. Antiviral efficacy of favipiravir against canine distemper virus infection in vitro. BMC Vet Res. 2019 Sep 2;15(1):316. doi: 10.1186/s12917-019-2057-8. PMID: 31477101; PMCID: PMC6720089. 2. Jochmans D, van Nieuwkoop S, Smits SL, Neyts J, Fouchier RA, van den Hoogen BG. Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4620-9. doi: 10.1128/AAC.00709-16. PMID: 27185803; PMCID: PMC4958190.
In vivo protocol: 1. Matz K, Emanuel J, Callison J, Gardner D, Rosenke R, Mercado-Hernandez R, Williamson BN, Feldmann H, Marzi A. Favipiravir (T-705) Protects IFNAR-/- Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner. Microorganisms. 2021 May 29;9(6):1178. doi: 10.3390/microorganisms9061178. PMID: 34072604. 2. Jacobs S, Wang L, Rosales Rosas AL, Van Berwaer R, Vanderlinden E, Failloux AB, Naesens L, Delang L. Favipiravir Does Not Inhibit Chikungunya Virus Replication in Mosquito Cells and Aedes aegypti Mosquitoes. Microorganisms. 2021 Apr 27;9(5):944. doi: 10.3390/microorganisms9050944. PMID: 33925738; PMCID: PMC8145424.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res. 2016 Feb;126:62-8. doi: 10.1016/j.antiviral.2015.12.006. Epub 2015 Dec 19. PubMed PMID: 26711718; PubMed Central PMCID: PMC4724333.

2: Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis. 2015 Dec 9. pii: jiv586. [Epub ahead of print] PubMed PMID: 26655300.

3: Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Muñoz-Fontela C, Günther S. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J Infect Dis. 2015 Nov 3. pii: jiv522. [Epub ahead of print] PubMed PMID: 26531247.

4: Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep. 2015 Oct 12;5:14775. doi: 10.1038/srep14775. PubMed PMID: 26456301; PubMed Central PMCID: PMC4600983.

5: Jin Z, Tucker K, Lin X, Kao CC, Shaw K, Tan H, Symons J, Behera I, Rajwanshi VK, Dyatkina N, Wang G, Beigelman L, Deval J. Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases. Antimicrob Agents Chemother. 2015 Dec;59(12):7504-16. doi: 10.1128/AAC.01391-15. Epub 2015 Sep 21. PubMed PMID: 26392512; PubMed Central PMCID: PMC4649231.

6: Madelain V, Oestereich L, Graw F, Nguyen TH, de Lamballerie X, Mentré F, Günther S, Guedj J. Ebola virus dynamics in mice treated with favipiravir. Antiviral Res. 2015 Nov;123:70-7. doi: 10.1016/j.antiviral.2015.08.015. Epub 2015 Sep 2. PubMed PMID: 26343011.

7: Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, Noto M, Oe T, Kaneko A. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74. doi: 10.5414/CP202388. PubMed PMID: 26308176.

8: Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, Hall JO. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015 Sep;121:132-7. doi: 10.1016/j.antiviral.2015.07.003. Epub 2015 Jul 14. PubMed PMID: 26186980; PubMed Central PMCID: PMC4536130.

9: Van Herp M, Declerck H, Decroo T. Favipiravir--a prophylactic treatment for Ebola contacts? Lancet. 2015 Jun 13;385(9985):2350. doi: 10.1016/S0140-6736(15)61095-9. PubMed PMID: 26088635.

10: Nau JY. [Ebola and favipiravir: when political preempts scientific communication]. Rev Med Suisse. 2015 Mar 4;11(464):574-5. French. PubMed PMID: 25924254.

11: Zhao Y, Harmatz JS, Epstein CR, Nakagawa Y, Kurosaki C, Nakamura T, Kadota T, Giesing D, Court MH, Greenblatt DJ. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br J Clin Pharmacol. 2015 Nov;80(5):1076-85. doi: 10.1111/bcp.12644. Epub 2015 Jun 8. PubMed PMID: 25808818; PubMed Central PMCID: PMC4631180.

12: Bouazza N, Treluyer JM, Foissac F, Mentré F, Taburet AM, Guedj J, Anglaret X, de Lamballerie X, Keïta S, Malvy D, Frange P. Favipiravir for children with Ebola. Lancet. 2015 Feb 14;385(9968):603-4. doi: 10.1016/S0140-6736(15)60232-X. PubMed PMID: 25706078.

13: Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015 Feb;9(1):79-81. doi: 10.1017/dmp.2014.151. Epub 2014 Dec 29. PubMed PMID: 25544306.

14: Mentré F, Taburet AM, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015 Feb;15(2):150-1. doi: 10.1016/S1473-3099(14)71047-3. Epub 2014 Nov 28. PubMed PMID: 25435054.

15: Arias A, Thorne L, Goodfellow I. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife. 2014 Oct 21;3:e03679. doi: 10.7554/eLife.03679. PubMed PMID: 25333492; PubMed Central PMCID: PMC4204012.

16: Park S, Kim JI, Lee I, Lee S, Hwang MW, Bae JY, Heo J, Kim D, Jang SI, Kim H, Cheong HJ, Song JW, Song KJ, Baek LJ, Park MS. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. PLoS One. 2014 Jul 3;9(7):e101325. doi: 10.1371/journal.pone.0101325. eCollection 2014. PubMed PMID: 24992479; PubMed Central PMCID: PMC4081560.

17: Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother. 2014 Oct;69(10):2770-84. doi: 10.1093/jac/dku209. Epub 2014 Jun 20. PubMed PMID: 24951535.

18: Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, Wurr S, Emmerich P, de Lamballerie X, Ölschläger S, Günther S. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis. 2014 May 1;8(5):e2804. doi: 10.1371/journal.pntd.0002804. eCollection 2014 May. PubMed PMID: 24786461; PubMed Central PMCID: PMC4006714.

19: Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2790. doi: 10.1371/journal.pntd.0002790. eCollection 2014 Apr. PubMed PMID: 24722586; PubMed Central PMCID: PMC3983105.

20: Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014 May;105:17-21. doi: 10.1016/j.antiviral.2014.02.014. Epub 2014 Feb 26. PubMed PMID: 24583123.


Franco EJ, Tao X, Hanrahan KC, Zhou J, Bulitta JB, Brown AN. Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. Microorganisms. 2021 Feb 2;9(2):307. doi: 10.3390/microorganisms9020307. PMID: 33540830; PMCID: PMC7912990.